Pall T. Onundarson: Would Modern Monitoring Alter VKAs Role in High-Risk COPD with AF Patients
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, shared on LinkedIn:
”Gundersen B-EVV, et al. in Denmark (BMJ Open Respir Res 2026;13:e003814. doi:10.1136/bmjresp-2025-003814) just published an observational study suggesting that VKAs are superior to DOAC drugs in moderate and severe COPD patients with concomitant atrial fibrillation.
The results are contrary to their hypothesis that VKA patients would fare worse as a consequence of loss of a protective effect of vitamin K in the lungs.
This adds to the data supporting a continued role for warfarin and VKAs in specific high-risk patient groups.
Albeit at the cost of inconvenience, RCTs have found that conventionally treated VKAs (mainly warfarin) are superior to DOAC drugs in certain high-risk conditions such as MHV, RHD, APLAS, frail elderly.
A caveat is that Gundersen´s study is not an RCT but there is still much to learn about warfarin/VKAs.
One wonders what the data would look like if warfarin had been monitored with a modern test and not the old PT-INR…”
Title: COPD and vitamin K antagonism: a cohort study of 1- year all- cause mortality and risk of hospitalisation due to a severe exacerbation
Authors: Bård-Emil Vang Vang Gundersen, Anna Kubel Vognsen, Josefin Eklöf, Pradeesh Sivapalan, Allan Linneberg, Tor Biering-Sørensen, Jens-Ulrik Stæhr Jensen
Read the Full Article on BMJ Open Respiratory Research

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series